Debated in Parliament on 9 Sep 2026.
Ms He Ting Ru asked the Coordinating Minister for Social Policies and Minister for Health given that Dengvaxia has been discontinued by the manufacturer (a) what support and advisory arrangements are in place for patients who have already been vaccinated or who are mid-course in the vaccination series, including access to remaining doses, clinical follow-up, and risk counselling; and (b) whether any alternatives are being explored.
The manufacturer for Dengvaxia has decided to discontinue the vaccine due to low global demand. No further follow up was required for individuals who had previously completed the recommended doses of Dengvaxia, since the discontinuation was not due to safety concerns.
When the discontinuation of Dengvaxia was announced in 2025, the manufacturer informed healthcare service providers of the stock availability, who could then in turn contact patients who had their first dose or second dose, to advise them on completing the vaccination series.
There are no new updates following the response to a Parliamentary question on the same topic dated 4 February 2026. [Please refer to "Update on Development of Potential Dengue Vaccine and Patient Support Service for Dengvaxia Vaccine", Official Report, 4 February 2026, Vol 96, Issue 16, Written Answers to Questions section.]
The Ministry of Health and relevant agencies will continue to monitor the development of dengue vaccines.
PAPERCUTS